192 related articles for article (PubMed ID: 36774428)
1. Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.
Huang L; McDade CL; Perdrizet JE; Wilson MR; Warren SA; Nzenze S; Sewdas R
Infect Dis Ther; 2023 Mar; 12(3):933-950. PubMed ID: 36774428
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.
Wilson M; Wasserman M; Jadavi T; Postma M; Breton MC; Peloquin F; Earnshaw S; McDade C; Sings H; Farkouh R
Infect Dis Ther; 2018 Sep; 7(3):353-371. PubMed ID: 29934878
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
[TBL] [Abstract][Full Text] [Related]
5. Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India.
Ghia CJ; Horn EK; Rambhad G; Perdrizet J; Chitale R; Wasserman MD
Infect Dis Ther; 2021 Dec; 10(4):2271-2288. PubMed ID: 34313958
[TBL] [Abstract][Full Text] [Related]
6. Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands.
Wilson M; McDade C; Beby-Heijtel AT; Waterval-Overbeek A; Sundaram V; Perdrizet J
Infect Dis Ther; 2023 Jul; 12(7):1809-1821. PubMed ID: 37318710
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants.
Perdrizet J; Horn EK; Nua W; Perez-Peralta J; Nailes J; Santos J; Ong-Lim A
Infect Dis Ther; 2021 Dec; 10(4):2625-2642. PubMed ID: 34591259
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
9. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy.
Ansaldi F; Pugh S; Amicizia D; Di Virgilio R; Trucchi C; Orsi A; Zollo A; Icardi G
Pathogens; 2020 Jan; 9(2):. PubMed ID: 31979079
[No Abstract] [Full Text] [Related]
10. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA
Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
Vaccine; 2024 Jun; ():. PubMed ID: 38879409
[TBL] [Abstract][Full Text] [Related]
13. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants.
Warren S; Barmpouni M; Kossyvaki V; Gourzoulidis G; Perdrizet J
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631937
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.
Kim HY; Park SB; Kang ES; Lee SM; Kim HJ; Wasserman M
Hum Vaccin Immunother; 2021 Mar; 17(3):909-918. PubMed ID: 32783576
[TBL] [Abstract][Full Text] [Related]
16. Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.
Pugh S; Wasserman M; Moffatt M; Marques S; Reyes JM; Prieto VA; Reijnders D; Rozenbaum MH; Laine J; Åhman H; Farkouh R
Infect Dis Ther; 2020 Jun; 9(2):305-324. PubMed ID: 32096144
[TBL] [Abstract][Full Text] [Related]
17. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia.
Ordóñez JE; Orozco JJ
Cost Eff Resour Alloc; 2015; 13():6. PubMed ID: 25878563
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
[TBL] [Abstract][Full Text] [Related]
20. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
